Bristol-Myers Squibb Pharmaceuticals Ltd (BMS)

Commercial

Carla Zema - Chief Investigator - Bristol-Myers Squibb Pharmaceuticals Limited - UK ( BMS )Andreas Ochs - Corresponding Applicant - Health Economics & Outcomes Research Ltd ( HEOR Ltd ) - Collaborator -Carmen Tsang - Collaborator - Health Economics & Outcomes Research Ltd ( HEOR Ltd )Jason Gordon - Collaborator - Health Economics & Outcomes Research Ltd ( HEOR Ltd )Maria Teresa Tome Esteban - Collaborator - St George'sUniversity of London

CPRD460

Hypertrophic cardiomyopathy (HCM) is a primary myocardial (i.e., heart muscle) disorder defined by thickening (i.e., hypertrophy) of the left ventricular (LV) wall that is unexplained by secondary causes. HCM, particularly obstructive HCM (oHCM) occurring when the LV wall thickens such that blood flow to the aorta is reduced/blocked, is associated with increased risks of heart failure (HF), atrial fibrillation/flutter, and sudden cardiac death, among other outcomes. Evidence from the US portends substantial unmet need and disease burden in HCM, which is likely exacerbated by the ongoing COVID-19 crisis given impacts on the accessibility of essential cardiology services. The current study proposes to use linked Clinical Practice Research Datalink (CPRD) / Hospital Episode Statistics (HES) data to study the impact of the COVID-19 crisis on treatments, natural history, health care resource utilisation, and medical cost of HCM in England. Specifically, we first seek to understand the epidemiology, patient characteristics, treatment history and treatment patterns, natural history, health care resource utilisation, and medical cost of HCM patients in England, and then more importantly, how treatment use and treatment patterns, natural history, health care resource utilisation, and medical cost changed after the initiation of COVID-19 restrictions in England, which are assumed to have begun in earnest 16th March, 2020. The public health benefit of this study is highlighted by the lack of comprehensive understanding of HCM in England and how the COVID-19 crisis has impacted treatments, natural history, health care resource utilisation, and medical cost in HCM in England.

With the linked CPRD-HES database, patients with HCM and its subtypes (oHCM, symptomatic oHCM, asymptomatic oHCM, and non-obstructive HCM [nHCM]) will be selected using validated codes indicative of diagnoses, symptoms, and procedures. A control cohort of patients with no HCM will be matched with a 3:1 ratio to each case on age, sex, region, and index year.

09/04/2021

Release